EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CRIS: Curis Inc

20 Nov 25 14:42
LAST:

1.117

CHANGE:
 0.01		OPEN:
1.140		HIGH:
1.210		ASK:
1.500		VOLUME:
126.1K
CHG(%):
1.19		PREV:
1.130		LOW:
1.100		BID:
1.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
20 Nov 251.1401.2101.1001.117126.1K
19 Nov 251.2501.2501.0601.130135.9K
18 Nov 251.2601.3201.1951.23092.1K
17 Nov 251.3001.3501.2201.230239.5K
14 Nov 251.1401.3501.1401.330130.0K
13 Nov 251.2201.2601.1301.13081.4K
12 Nov 251.2701.3491.1801.23075.2K
11 Nov 251.3001.3101.2401.25039.4K
10 Nov 251.3101.3551.3001.31038.5K
07 Nov 251.3501.3901.2101.310233.9K

PROFILE

Name:Curis Inc
About:Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:Building C, Lexington, MA, United States, 02421
Website:https://www.curis.com
CUSIP:231269200
CIK:0001108205
ISIN:US2312693094
FIGI:BBG000C1GTC9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.218.1%
MA10:1.239.9%
MA20:1.3622.0%
MA50:1.5236.3%
MA100:1.6345.8%
MA200:1.9675.3%
RSI14:28.12 
WPR14:-100.00 
MTM14:-0.36
ROC14:-0.25 
ATR:0.13 
Week High:1.3520.9%
Week Low:1.065.3%
Month High:1.6850.5%
Month Low:1.0675.3%
Year High:4.70321.0%
Year Low:1.029.5%
Volatility:6.54 

RECENT SPLITS

Date Ratio
29 Sep 20231-20
30 May 20181-5